PROVECTUS ANNOUNCES RESULTS FROM ELICITATION STUDY OF PATIENT-PERCEIVED IMPACTS FROM STAGE III AND EARLY-STAGE IV MELANOMA
October 23, 2017 08:00 ET
|
Provectus Biopharmaceuticals Inc.
– Key impacts comprised worry/concern, altered clothing choices, and limitations to physical functioning – – Study results further support the clinical significance of Provectus’ ongoing,...
PROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMA
October 18, 2017 09:38 ET
|
Provectus Biopharmaceuticals Inc.
– Adverse events consistent with established patterns for each drug; no unexpected toxicities observed – 50% overall objective response rate; 10% complete response; highest responses observed in...